Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)898.92m
- Net income in CNY-375.51m
- Incorporated2015
- Employees1.09k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609913
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions Ltd | 825.18m | -377.67m | 9.12bn | 1.17k | -- | 10.77 | -- | 11.05 | -0.9121 | -0.9121 | 1.99 | 2.05 | 0.3533 | 1.00 | 6.83 | 707,092.40 | -16.17 | -23.62 | -26.76 | -30.81 | 69.81 | 79.76 | -45.77 | -106.72 | 0.716 | -27.47 | 0.4531 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 169.42m | -1.07bn | 9.54bn | 1.40k | -- | 4.98 | -- | 56.32 | -2.69 | -2.69 | 0.424 | 4.80 | 0.0379 | 0.089 | 9.74 | 113,628.50 | -24.10 | -37.61 | -30.74 | -45.95 | 90.50 | 81.54 | -636.41 | -2,112.26 | 1.25 | -41.98 | 0.5339 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| InnoCare Pharma Ltd | 898.92m | -375.51m | 12.73bn | 1.09k | -- | 3.55 | -- | 14.16 | -0.2325 | -0.2325 | 0.537 | 3.86 | 0.0922 | 1.32 | 3.73 | 825,457.90 | -4.02 | -- | -4.78 | -- | 84.50 | -- | -43.57 | -- | 7.65 | -- | 0.1547 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 2.12bn | -912.86k | 12.97bn | 2.59k | -- | 1.76 | -- | 6.10 | -0.0064 | -0.0064 | 2.82 | 10.68 | 0.2151 | 0.7714 | 7.32 | -- | -0.09 | 8.99 | -0.106 | 11.07 | 31.83 | 46.76 | -0.4184 | 32.01 | 2.85 | 1.25 | 0.0089 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| RemeGen Co Ltd | 1.52bn | -1.55bn | 16.25bn | 3.62k | -- | 8.46 | -- | 10.67 | -2.88 | -2.88 | 2.83 | 4.35 | 0.2712 | 0.4446 | 5.00 | 421,122.40 | -27.65 | -18.66 | -36.21 | -23.69 | 78.65 | 81.64 | -101.95 | -102.21 | 0.9558 | -32.19 | 0.5167 | -- | 40.26 | 141.16 | -51.30 | -- | 59.07 | -- |
| Sinocelltech Group Ltd | 2.45bn | -24.64m | 17.73bn | 2.33k | -- | -- | -- | 7.25 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
Data as of Nov 22 2024. Currency figures normalised to InnoCare Pharma Ltd's reporting currency: Chinese Yuan Renminbi CNY
27.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 29.63m | 11.39% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 9.68m | 3.72% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 7.74m | 2.98% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 5.34m | 2.05% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 5.21m | 2.00% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 5.00m | 1.92% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 2.43m | 0.93% |
| Golden Eagle Asset Management Co., Ltd.as of 30 Jun 2024 | 2.13m | 0.82% |
| China Fund Management Co., Ltd.as of 30 Jun 2024 | 2.00m | 0.77% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 1.82m | 0.70% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
